Cargando…

Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment

Ischemia and reperfusion injury (IRI) is a common complication caused by inflammation and oxidative stress resulting from liver surgery. Current therapeutic strategies do not present the desirable efficacy, and severe side effects can occur. To overcome these drawbacks, new therapeutic alternatives...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira-Silva, Margarida, Faria-Silva, Catarina, Carvalheiro, Manuela C., Simões, Sandra, Marinho, H. Susana, Marcelino, Paulo, Campos, Maria Celeste, Metselaar, Josbert M., Fernandes, Eduarda, Baptista, Pedro V., Fernandes, Alexandra R., Corvo, Maria Luísa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779145/
https://www.ncbi.nlm.nih.gov/pubmed/35057000
http://dx.doi.org/10.3390/pharmaceutics14010104
_version_ 1784637499639857152
author Ferreira-Silva, Margarida
Faria-Silva, Catarina
Carvalheiro, Manuela C.
Simões, Sandra
Marinho, H. Susana
Marcelino, Paulo
Campos, Maria Celeste
Metselaar, Josbert M.
Fernandes, Eduarda
Baptista, Pedro V.
Fernandes, Alexandra R.
Corvo, Maria Luísa
author_facet Ferreira-Silva, Margarida
Faria-Silva, Catarina
Carvalheiro, Manuela C.
Simões, Sandra
Marinho, H. Susana
Marcelino, Paulo
Campos, Maria Celeste
Metselaar, Josbert M.
Fernandes, Eduarda
Baptista, Pedro V.
Fernandes, Alexandra R.
Corvo, Maria Luísa
author_sort Ferreira-Silva, Margarida
collection PubMed
description Ischemia and reperfusion injury (IRI) is a common complication caused by inflammation and oxidative stress resulting from liver surgery. Current therapeutic strategies do not present the desirable efficacy, and severe side effects can occur. To overcome these drawbacks, new therapeutic alternatives are necessary. Drug delivery nanosystems have been explored due to their capacity to improve the therapeutic index of conventional drugs. Within nanocarriers, liposomes are one of the most successful, with several formulations currently in the market. As improved therapeutic outcomes have been demonstrated by using liposomes as drug carriers, this nanosystem was used to deliver quercetin, a flavonoid with anti-inflammatory and antioxidant properties, in hepatic IRI treatment. In the present work, a stable quercetin liposomal formulation was developed and characterized. Additionally, an in vitro model of ischemia and reperfusion was developed with a hypoxia chamber, where the anti-inflammatory potential of liposomal quercetin was evaluated, revealing the downregulation of pro-inflammatory markers. The anti-inflammatory effect of quercetin liposomes was also assessed in vivo in a rat model of hepatic IRI, in which a decrease in inflammation markers and enhanced recovery were observed. These results demonstrate that quercetin liposomes may provide a significant tool for addressing the current bottlenecks in hepatic IRI treatment.
format Online
Article
Text
id pubmed-8779145
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87791452022-01-22 Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment Ferreira-Silva, Margarida Faria-Silva, Catarina Carvalheiro, Manuela C. Simões, Sandra Marinho, H. Susana Marcelino, Paulo Campos, Maria Celeste Metselaar, Josbert M. Fernandes, Eduarda Baptista, Pedro V. Fernandes, Alexandra R. Corvo, Maria Luísa Pharmaceutics Article Ischemia and reperfusion injury (IRI) is a common complication caused by inflammation and oxidative stress resulting from liver surgery. Current therapeutic strategies do not present the desirable efficacy, and severe side effects can occur. To overcome these drawbacks, new therapeutic alternatives are necessary. Drug delivery nanosystems have been explored due to their capacity to improve the therapeutic index of conventional drugs. Within nanocarriers, liposomes are one of the most successful, with several formulations currently in the market. As improved therapeutic outcomes have been demonstrated by using liposomes as drug carriers, this nanosystem was used to deliver quercetin, a flavonoid with anti-inflammatory and antioxidant properties, in hepatic IRI treatment. In the present work, a stable quercetin liposomal formulation was developed and characterized. Additionally, an in vitro model of ischemia and reperfusion was developed with a hypoxia chamber, where the anti-inflammatory potential of liposomal quercetin was evaluated, revealing the downregulation of pro-inflammatory markers. The anti-inflammatory effect of quercetin liposomes was also assessed in vivo in a rat model of hepatic IRI, in which a decrease in inflammation markers and enhanced recovery were observed. These results demonstrate that quercetin liposomes may provide a significant tool for addressing the current bottlenecks in hepatic IRI treatment. MDPI 2022-01-03 /pmc/articles/PMC8779145/ /pubmed/35057000 http://dx.doi.org/10.3390/pharmaceutics14010104 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ferreira-Silva, Margarida
Faria-Silva, Catarina
Carvalheiro, Manuela C.
Simões, Sandra
Marinho, H. Susana
Marcelino, Paulo
Campos, Maria Celeste
Metselaar, Josbert M.
Fernandes, Eduarda
Baptista, Pedro V.
Fernandes, Alexandra R.
Corvo, Maria Luísa
Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment
title Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment
title_full Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment
title_fullStr Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment
title_full_unstemmed Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment
title_short Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment
title_sort quercetin liposomal nanoformulation for ischemia and reperfusion injury treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779145/
https://www.ncbi.nlm.nih.gov/pubmed/35057000
http://dx.doi.org/10.3390/pharmaceutics14010104
work_keys_str_mv AT ferreirasilvamargarida quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT fariasilvacatarina quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT carvalheiromanuelac quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT simoessandra quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT marinhohsusana quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT marcelinopaulo quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT camposmariaceleste quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT metselaarjosbertm quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT fernandeseduarda quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT baptistapedrov quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT fernandesalexandrar quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment
AT corvomarialuisa quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment